BibbInstruments

BibbInstruments Inventory/Revenue

The Inventory to Revenue Ratio of BibbInstruments (BIBB.SL) as of Nov 3, 2026 is 361.60 %.

Inventory/Revenue

361.60 %

Last updated:

Inventory to Revenue Ratio of BibbInstruments is 2025 361.60 % . Inventory to Revenue Ratio of BibbInstruments was 2024 0.00 . It decreases by % higher compared to the previous year.

The BibbInstruments Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2016
19,875.00 SEK
Jan 1, 2017
619.53 SEK
Jan 1, 2018
185.04 SEK
Jan 1, 2019
172.98 SEK
Jan 1, 2020
37.34 SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2025
361.60 SEK
The BibbInstruments Inventory/Revenue history
YEARInventory/RevenueYoY
361.60 %—
0.00-100.00%
37.34 %-78.41%
172.98 %-6.52%
185.04 %-70.13%
619.53 %-96.88%
19,875.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Inventory to Revenue Ratio of BibbInstruments is 361.60 % in 2025.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's BibbInstruments with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BibbInstruments

All Key Metrics — BibbInstruments